Bob, T. L., Velcheti, V., Price, T. J., Hong, D. S., Fakih, M., Kim, D.-W., … Skoulidis, F. (2022). Largest evaluation of acquired resistance to sotorasib in KRAS p.G12C-mutated non-small cell lung cancer (NSCLC) and colorectal cancer (CRC): Plasma biomarker analysis of CodeBreaK100. In JOURNAL OF CLINICAL ONCOLOGY (Vol. 40).

Bob, T Li, Vamsidhar Velcheti, Timothy Jay Price, David S. Hong, Marwan Fakih, Dong-Wan Kim, Gerald Steven Falchook, et al. “Largest evaluation of acquired resistance to sotorasib in KRAS p.G12C-mutated non-small cell lung cancer (NSCLC) and colorectal cancer (CRC): Plasma biomarker analysis of CodeBreaK100.” In JOURNAL OF CLINICAL ONCOLOGY, Vol. 40, 2022.

Bob TL, Velcheti V, Price TJ, Hong DS, Fakih M, Kim D-W, et al. Largest evaluation of acquired resistance to sotorasib in KRAS p.G12C-mutated non-small cell lung cancer (NSCLC) and colorectal cancer (CRC): Plasma biomarker analysis of CodeBreaK100. In: JOURNAL OF CLINICAL ONCOLOGY. 2022.

Bob, T. Li, et al. “Largest evaluation of acquired resistance to sotorasib in KRAS p.G12C-mutated non-small cell lung cancer (NSCLC) and colorectal cancer (CRC): Plasma biomarker analysis of CodeBreaK100.” JOURNAL OF CLINICAL ONCOLOGY, vol. 40, no. 16, 2022.

Bob TL, Velcheti V, Price TJ, Hong DS, Fakih M, Kim D-W, Falchook GS, Delord J-P, Dy GK, Ramalingam SS, Strickler JH, Kurata T, Wolf J, Sacher AG, Addeo A, Prenen H, Hindoyan A, Anderson A, Ang A, Skoulidis F. Largest evaluation of acquired resistance to sotorasib in KRAS p.G12C-mutated non-small cell lung cancer (NSCLC) and colorectal cancer (CRC): Plasma biomarker analysis of CodeBreaK100. JOURNAL OF CLINICAL ONCOLOGY. 2022.